Filing Details

Accession Number:
0001562180-23-002198
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-03 08:01:05
Reporting Period:
2023-03-01
Accepted Time:
2023-03-03 08:01:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA Pharmaceutical Preparations (2834) 208756903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1669737 Michel Dahan C/O Akebia Therapeutics, Inc.
245 First Street
Cambridge MA 02142
Svp, Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-01 8,058 $0.88 281,869 No 4 S Direct
Common Stock Disposition 2023-03-01 10,476 $0.88 271,393 No 4 S Direct
Common Stock Disposition 2023-03-01 1,878 $0.88 269,515 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
  2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
  3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.